GLP-1 analogue - semaglutide for Obesity

Phase-Based Progress Estimates
ObesityGLP-1 analogue - semaglutide - Drug
18 - 55
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug to see if it can help people with obesity lose weight by reducing hunger, cravings, and stress.

Treatment Effectiveness

Study Objectives

3 Primary · 3 Secondary · Reporting Duration: week 0, 4, 8, 12

Week 12
Change in Craving
Change in Food Intake
Change in Hunger
Week 0
Change in food intake - real-life
Change in stress
weekly for 12 weeks
Change in weight

Trial Safety

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

96 Total Participants · 2 Treatment Groups

Primary Treatment: GLP-1 analogue - semaglutide · Has Placebo Group · Phase 1

Experimental Group · 1 Intervention: GLP-1 analogue - semaglutide · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 0, 4, 8, 12

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,679 Previous Clinical Trials
21,087,943 Total Patients Enrolled
58 Trials studying Obesity
248,096 Patients Enrolled for Obesity
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,148 Previous Clinical Trials
4,074,683 Total Patients Enrolled
403 Trials studying Obesity
492,889 Patients Enrolled for Obesity
Ania Jastreboff, MD, PhDPrincipal InvestigatorInternal Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology);
Rajita Sinha, PhDPrincipal InvestigatorPsychiatry; Director Yale Stress Center
13 Previous Clinical Trials
1,943 Total Patients Enrolled
3 Trials studying Obesity
314 Patients Enrolled for Obesity

Eligibility Criteria

Age 18 - 55 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
She can speak English and read English well enough to complete study evaluations.
Can provide written or verbal consent that is informed.
This text is saying that there is no history of people with an HgbA1c level of less than 6.5%.

Who else is applying?

What state do they live in?
New York66.7%
How old are they?
18 - 65100.0%
What site did they apply to?
The Yale Stress Center: Yale University100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria66.7%
Met criteria33.3%
Why did patients apply to this trial?
  • "I’ve tried other over the counter weight loss aids but nothing worked. I’m interested in trying new drugs or technologies that might prove to help me lose my belly fat"
How many prior treatments have patients received?